[The Europe against immature lung (EURAIL) project. Strategies for the prevention and treatment of lung immaturity in neonates]

An Pediatr (Barc). 2003 Jan;58(1):45-51. doi: 10.1016/s1695-4033(03)77990-9.
[Article in Spanish]

Abstract

Objective: To determine clinical practice variability in the prevention and postnatal treatment of lung immaturity in Spain.

Patients and methods: Cross-sectional study within a larger study in 13 European countries. Data were obtained from the medical records of all very low birth weight (VLBW) infants born in participating centers, without other instrumentation.

Results: A questionnaire was sent to 213 centers. Seventy-two (34 %) responded, with 162,157 births (40 % of total births in 1999). Eight percent of infants were of low birth weight, 1.2 % (2,015) of very low birth weight and 0.45 % were of extremely low birth weight. A total of 52.2 % of VLBW infants received at least one dose of prenatal steroids, 28.8 % received a full course and 9.3 % received more than one cycle. All centres used surfactant and 76.8 % had a written protocol. Forty-one percent of VLBW infants were intubated, 47.6 % required mechanical ventilation for more than 6 hours, and 5 % underwent continuous positive airway pressure. A total of 80.4 % used postnatal steroids, half of them for chronic lung disease prevention, and 83.4 % used steroids to treat this disease. Steroids were most frequently indicated at 7-14 days of life for 3-9 days. The most important causes of neonatal morbidity were chronic lung disease in 14 %, ductus arteriosus in 16.7 %, intraventricular hemorrhage in 8.5 %, and necrotizing enterocolitis in 7.3 %.

Conclusions: Prenatal exposure to steroids was low. Repeat cycles and postnatal steroid use to prevent chronic lung disease was high. Recent scientific evidence on the use of pre- and postnatal steroids should be more widely disseminated.

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Betamethasone / therapeutic use
  • Cross-Sectional Studies
  • Europe
  • Humans
  • Incidence
  • Infant, Newborn
  • Infant, Premature
  • Infant, Premature, Diseases / epidemiology
  • Infant, Premature, Diseases / prevention & control*
  • Infant, Premature, Diseases / therapy
  • Lung / abnormalities*
  • Pulmonary Surfactants / therapeutic use
  • Spain
  • Surveys and Questionnaires

Substances

  • Pulmonary Surfactants
  • Betamethasone